Other immune checkpoint molecules, such as LAG3, TIM-3, 4–1BB, CD40, and OX40, can also be targeted and combined with PD-1/PD-L1 or CTLA-4 blockade in patients with HCC (NCT03005782, NCT03099109, NCT03241173). Here, CD274 is linked to hepatocellular carcinoma.